An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Repare Therapeutics Inc. (Nasdaq: RPTX) appoints Dr. Steven H. Stein to its Board of Directors, thanking Todd Foley for his contributions. Dr. Stein brings extensive experience in oncology drug development, currently serving as the Chief Medical Officer of Incyte The Company looks forward to his guidance as it advances its precision oncology pipeline.
Repare Therapeutics Inc. (Nasdaq: RPTX) nomina il Dr. Steven H. Stein nel suo Consiglio di Amministrazione, ringraziando Todd Foley per i suoi contributi. Il Dr. Stein apporta una vasta esperienza nello sviluppo di farmaci oncologici, attualmente ricoprendo la posizione di Direttore Medico presso Incyte. L'azienda attende con fiducia la sua guida mentre progredisce nel suo percorso di oncologia di precisione.
Repare Therapeutics Inc. (Nasdaq: RPTX) ha nombrado al Dr. Steven H. Stein a su Junta Directiva, agradeciendo a Todd Foley por sus contribuciones. El Dr. Stein trae consigo una amplia experiencia en el desarrollo de medicamentos oncológicos, actualmente sirviendo como Director Médico de Incyte. La compañía espera con interés su orientación mientras avanza en su cartera de oncología de precisión.
Repare Therapeutics Inc. (나스닥: RPTX)가 스티븐 H. 스타인 박사를 이사회에 임명하며, 토드 폴리의 공헌에 감사를 표했습니다. 스타인 박사는 현재 Incyte의 최고 의료 책임자로 재직 중이며, 항암 약물 개발 분야에서 풍부한 경험을 가지고 있습니다. 회사는 정밀 종양학 파이프라인을 발전시키면서 그의 지도를 기대하고 있습니다.
Repare Therapeutics Inc. (Nasdaq: RPTX) a nommé le Dr. Steven H. Stein à son Conseil d'Administration, en remerciant Todd Foley pour ses contributions. Le Dr. Stein apporte une expérience considérable dans le développement de médicaments oncologiques, occupant actuellement le poste de Directeur Médical chez Incyte. L'entreprise se réjouit de bénéficier de ses conseils alors qu'elle fait avancer son pipeline en oncologie de précision.
Repare Therapeutics Inc. (Nasdaq: RPTX) hat Dr. Steven H. Stein in seinen Vorstand berufen und dankt Todd Foley für seine Beiträge. Dr. Stein bringt umfangreiche Erfahrungen in der Entwicklung von Onkologika mit, da er derzeit als Chief Medical Officer bei Incyte tätig ist. Das Unternehmen freut sich auf seine Unterstützung, während es seine Präzisionsonkologie-Pipeline vorantreibt.
Positive
Appointment of Dr. Steven H. Stein to the Board of Directors brings valuable expertise in oncology drug development
Todd Foley's decision not to stand for re-election as a director after seven years of service
Dr. Stein's background includes leadership roles at Incyte , Novartis Oncology, and GlaxoSmithKline
Repare Therapeutics expresses gratitude to Todd Foley for his dedication and contributions to the Company's growth
Dr. Stein's appointment signifies a critical time in Repare's evolution and growth in the precision oncology sector
Negative
None.
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company’s upcoming annual meeting of shareholders in June 2024. The Company also announces that Todd Foley has decided not to stand for re-election as a director of the Company following the end of his current term as a Class I director on June 17, 2024, after serving more than seven years on the Board.
“On behalf of the Company and our Board of Directors, we thank Todd for his dedication and partnership, which have played a crucial role in shaping Repare into the leading precision oncology company that it is today. Todd has made tremendous contributions during the past seven years, and I am grateful to him and his team at MPM for their continued support,” said Lloyd M. Segal, President and Chief Executive Officer of Repare. “We are also honored to welcome Dr. Stein to our Board. His deep experience, proven track record and accomplishments in oncology clinical drug development will provide valuable guidance as Repare’s pipeline advances to later stages of development.”
“It has been a pleasure collaborating with the Repare management team and Board throughout its evolution into a multi-pronged clinical development company," said Todd Foley, Managing Director at MPM BioImpact. "I look forward to the ongoing advancement of Repare’s pipeline and its continued progress as a leading precision oncology company."
Dr. Stein currently serves as the Chief Medical Officer of Incyte Corporation, a position he has held since March 2015. At Incyte, he leads all medical and scientific activities involving clinical development, clinical operations, pharmacovigilance, clinical pharmacology, scientific communications and medical affairs. Prior to joining Incyte, from May 2011 to February 2015, Dr. Stein served as the Senior Vice President and Head of U.S. Clinical Development and Medical Affairs at Novartis Oncology. Prior to then, he was employed by GlaxoSmithKline from February 2004 to April 2011, serving first as its Head of Medicines Development for Hematology and Supportive Care and then as its Vice President, Global Oncology, Clinical Development. Dr. Stein also previously served on the board of directors of Kura Oncology, Inc. from 2017 until May 2023.Dr. Stein earned his MBBCH from the University of Witwatersrand in Johannesburg, South Africa. He has authored more than 100 scientific papers and presentations and is an Adjunct Assistant Professor in the School of Medicine, University of Pennsylvania. Dr. Stein is also an active member of several professional and scientific societies and academic committees.
“I am honored to join the Board of Directors at Repare at such a critical time in the Company’s growth and evolution, and am looking forward to working with its leadership team to deliver on the Company’s mission to develop synthetic lethal medicines that meaningfully improve the lives of cancer patients,” said Dr. Stein.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1/2 clinical development; camonsertib (also known as RP-3500), a potential leading ATR inhibitor currently in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical Polθ ATPase inhibitor program; as well as additional, undisclosed preclinical programs. For more information, please visit reparerx.com.
SNIPRx® is a registered trademark of Repare Therapeutics Inc.
repare therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. its approach integrates insights from several fields of cell biology including dna repair and synthetic lethality. repare’s platform combines a proprietary, high throughput, crispr‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics. the company is backed by leading global healthcare investors including founding investor versant ventures and mpm capital. for additional information, please visit www.reparerx.com.
